Despite a 6-month improvement of 2-year-overall survival in pancreatic cancer patients, Norwegian cancer immunotherapy specialist Targovax ASA will terminate development of TG01 in this indication. Instead, development of RAS neoantigen-targeting cancer vaccines will be pushed in colorectal cancer.
British T cell player, Autolus Therapeutics Ltd. wants to go NASDAQ selling 7.8 million American Depositary Shares (ADSs) at at least US-$15, totaling in US$117m. Through a greenshoe option, Autolus want to offer additional 1,171,875 ADS at the IPO price.
EU Commissioners Jyrki Katainen and Carlos Moedas proposed a budget increase of 25% for the next European Research and Innovation programme Horizon Europe (2021-27) vs Horizon 2020. However MEPs said that the new moonshot research section EIC is underfunded. Furthermore, the current funding quote of 11% was too low compared to other international excellence programmes.
Alkermes plc (Dublin) received a US$50m milestone payment from Biogen after review of preliminary Phase III gastrointestinal tolerability data of Alkermes’ relapsing-remitting multiple sclerosis candidate diroximel fumarate (BIIB098).
Austrian arenaviral vector technology specialist Hookipa Biotech AG (Vienna, Austria) has licenced its TheraT and Vaxwave technologies exclusively to Gilead Sciences Inc. to develop and globally commercialise vaccines against the human immunodeficiency virus (HIV) and the hepatitis B virus (HBV).
The US FDA has accepted a supplemental BLA to Roche’s existing market approval of the new hemophilia A treatment Hemlibra (emicizumab), which could significantly extend the patient group covered by the label.
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended nine medicines for approval, including two orphan medicines, at its May 2018 meeting.
French researchers have found a key driver of chronic epilepsy.
Brain disease specialist Denali Therapeutics will buy all outstanding shares in British F-Star Gamma Ltd from F-Star instead licencing bispecific antibody candidates that can cross the blood-brain barrier (BBB) co-developed under an agreement dating back to 2016.
Roche announced that atezolimumab plus chemotherapy met its co-primary endpoints of overall survival (OS) and progression-free survival (PFS) as first-line treatment of stage IV nonsquamous non small cell lung cancer (NSCLC).